RNA Technologies in Cardiovascular Medicine and Research / Edition 1by Volker A. Erdmann (Deceased)
Pub. Date: 07/09/2008
Publisher: Springer Berlin Heidelberg
Cardiovascular disease is the number one cause of death worldwide. In 2005 17.5 million people, representing 30% of all global deaths, died of cardiovascular disease. For this reason every effort needs to be made to improve the early diagnosis and treatment procedures for combating this disease. This book - edited by Professors Erdmann and Barciszewski, both
Cardiovascular disease is the number one cause of death worldwide. In 2005 17.5 million people, representing 30% of all global deaths, died of cardiovascular disease. For this reason every effort needs to be made to improve the early diagnosis and treatment procedures for combating this disease. This book - edited by Professors Erdmann and Barciszewski, both internationally recognised experts in the field of RNA molecular biology, and Professor Poller, an internationally respected expert in cardiology - will offer more than an introduction to these fields. More importantly, it will also lead the reader to the newest developments in RNA methods and technologies and show how they are currently employed for the diagnosis and treatment of cardiovascular disease. This book is also a must for all those interested in knowing more about the molecular medicine of tomorrow and how it will be revolutionised by its newest approach - RNA technologies.
- Springer Berlin Heidelberg
- Publication date:
- Edition description:
- Product dimensions:
- 6.20(w) x 9.40(h) x 1.10(d)
Table of Contents
Preface.- Part I - MicroRNA.- An overview of microRNA. MicroRNAs and their potential. miRNAs and their emerging role in cardiac hypertrophy. MicroRNAs and the control of heart pathophysiology. MicroRNA systems biology.- Part II - RNA interference.- Targeting viral heart disease by RNA interference. Design of siRNAs and shRNAs for RNA interference: possible clinical applications. RNA interference and microRNA modulation for the treatment of cardiac disorders. Cardiac delivery of nucleic acids by transcriptional and transductional targeting of adeno-associated viral vectors.- Part III - Ribozymes.- Characterization of hammerhead ribozymes potentialy suitable for the treatment of hyperproliferative vascular diseases. Applications of ribozymes and pyrrole-imidazole polyamides for cardiovascular and renal diseases.- Part IV. - Noncoding, aptamer and antisense RNAs.- Noncoding RNAs in human diseases. Aptamers and siRNAs in cardiovascular disease. Nucleic Acid Aptamers for Cardiovascular Therapeutics. NFkB decoy oligodeoxynucleotide-based therapy in cardiovascular diseases. Antisense therapy for restenosis following percutaneous coronary intervention.Toxic RNA in pathogenesis of human neuromuscular disorders.
and post it to your social network
Most Helpful Customer Reviews
See all customer reviews >